oxycodone

Summary

Summary: Semisynthetic derivative of CODEINE that acts as a narcotic analgesic more potent and addicting than codeine.

Top Publications

  1. pmc Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone
    Irfan A Dhalla
    Department of Medicine, University of Toronto, and the Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario
    CMAJ 181:891-6. 2009
  2. ncbi Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III
    Marc Afilalo
    Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Clin Drug Investig 30:489-505. 2010
  3. ncbi Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models
    Kazuhisa Minami
    Pain and Neurology, Discovery Research Laboratories, Shionogi and Co, Ltd, Japan
    J Pharmacol Sci 111:60-72. 2009
  4. ncbi Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia
    S T Zwisler
    Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
    Acta Anaesthesiol Scand 54:232-40. 2010
  5. ncbi A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model
    Camilla Staahl
    Center for Visceral Biomechanics and Pain, Department of Gastroenterology, University Hospital Aalborg, Denmark
    Pain 123:28-36. 2006
  6. ncbi Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers
    Jose de Leon
    J Clin Psychopharmacol 23:420-1. 2003
  7. ncbi Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy
    C Peter N Watson
    University of Toronto, Toronto, ON, Canada
    Pain 105:71-8. 2003
  8. pmc The promotion and marketing of oxycontin: commercial triumph, public health tragedy
    Art Van Zee
    Stone Mountain Health Services, St Charles Clinic, St Charles, VA 24282, USA
    Am J Public Health 99:221-7. 2009
  9. ncbi The pharmacokinetics of oxycodone
    Ralph A Lugo
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City 84112 5820, USA
    J Pain Palliat Care Pharmacother 18:17-30. 2004
  10. ncbi A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy
    Harald Lenz
    University of Oslo, Faculty Division Ullevaal University Hospital, Oslo, Norway
    Anesth Analg 109:1279-83. 2009

Detail Information

Publications298 found, 100 shown here

  1. pmc Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone
    Irfan A Dhalla
    Department of Medicine, University of Toronto, and the Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario
    CMAJ 181:891-6. 2009
    Opioid-related mortality appears to be increasing in Canada. We examined the true extent of the problem and the impact of the introduction of long-acting oxycodone.
  2. ncbi Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III
    Marc Afilalo
    Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Clin Drug Investig 30:489-505. 2010
    ..Tapentadol is a novel, centrally acting analgesic with mu-opioid receptor agonist and norepinephrine reuptake inhibitor activity...
  3. ncbi Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models
    Kazuhisa Minami
    Pain and Neurology, Discovery Research Laboratories, Shionogi and Co, Ltd, Japan
    J Pharmacol Sci 111:60-72. 2009
    Morphine, oxycodone, and fentanyl are clinically prescribed drugs for the management of severe pain. We investigated whether these opioids possess different efficacy profiles on several types of pain in mouse pain models...
  4. ncbi Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia
    S T Zwisler
    Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
    Acta Anaesthesiol Scand 54:232-40. 2010
    b>Oxycodone is a semi-synthetic opioid with a mu-receptor agonist-mediated effect in several pain conditions, including post-operative pain...
  5. ncbi A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model
    Camilla Staahl
    Center for Visceral Biomechanics and Pain, Department of Gastroenterology, University Hospital Aalborg, Denmark
    Pain 123:28-36. 2006
    ..In animal experiments, oxycodone has shown different effects compared to morphine, and clinical observations have shown that oxycodone may ..
  6. ncbi Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers
    Jose de Leon
    J Clin Psychopharmacol 23:420-1. 2003
  7. ncbi Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy
    C Peter N Watson
    University of Toronto, Toronto, ON, Canada
    Pain 105:71-8. 2003
    ..Painful neuropathy is one of the most common long-term complications of diabetes mellitus and often proves difficult to relieve...
  8. pmc The promotion and marketing of oxycontin: commercial triumph, public health tragedy
    Art Van Zee
    Stone Mountain Health Services, St Charles Clinic, St Charles, VA 24282, USA
    Am J Public Health 99:221-7. 2009
    ....
  9. ncbi The pharmacokinetics of oxycodone
    Ralph A Lugo
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City 84112 5820, USA
    J Pain Palliat Care Pharmacother 18:17-30. 2004
    b>Oxycodone is among the most commonly used opioid analgesics for the relief of moderate-to-severe pain and is pharmacodynamically comparable to morphine...
  10. ncbi A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy
    Harald Lenz
    University of Oslo, Faculty Division Ullevaal University Hospital, Oslo, Norway
    Anesth Analg 109:1279-83. 2009
    In this study, we investigated the dose requirements, pain relief, and side effects of oxycodone versus morphine after surgery with visceral pain.
  11. ncbi The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes
    Stine T Zwisler
    Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
    Fundam Clin Pharmacol 24:517-24. 2010
    ..gene and C3435T and G2677T/A in the ABCB1 gene and altered antinociceptive effect and adverse drug reactions of oxycodone. Thirty-three healthy subjects exposed to experimental pain including electrical stimulation and the cold ..
  12. ncbi The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain
    Michael A Ashburn
    Department of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Anesth Analg 112:693-702. 2011
    ..In this study we evaluated the efficacy and safety of treatment with fentanyl buccal tablet (FBT) in comparison with immediate-release oxycodone in alleviating BTP in opioid-tolerant patients with chronic pain.
  13. ncbi Opioid formulations designed to resist/deter abuse
    Robert B Raffa
    Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania 19140, USA
    Drugs 70:1657-75. 2010
    ..These drugs include extended-release morphine with sequestered naloxone (Embeda), controlled-release oxycodone in a high-viscosity hard gelatin capsule (Remoxy) and an immediate-release oxycodone tablet with subtherapeutic ..
  14. ncbi Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
    Oliver Kummer
    Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital, 4031 Basel, Switzerland
    Eur J Clin Pharmacol 67:63-71. 2011
    The main metabolic pathways of oxycodone, a potent opioid analgetic, are N-demethylation (CYP3A4) to inactive noroxycodone and O-demethylation (CYP2D6) to active oxymorphone...
  15. ncbi Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach
    Karen Reimer
    Mundipharma Research GmbH and Co KG, Limburg Lahn, Germany
    Pharmacology 83:10-7. 2009
    ..Combination therapy with prolonged-release (PR) oxycodone plus PR naloxone has been shown to provide effective analgesia while preventing or reducing constipation...
  16. ncbi Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain
    Katri Elina Clemens
    University of Bonn, Malteser Hospital Bonn Rhein Sieg, Centre for Palliative Medicine, Department of Science and Research, Von Hompesch Str 1, D 53123 Bonn, Germany
    Expert Opin Pharmacother 11:297-310. 2010
    ..The combination of the strong opioid oxycodone and the opioid antagonist naloxone has the potential to prevent opioid-induced bowel dysfunction (OIBD) while ..
  17. ncbi Major increases in opioid analgesic abuse in the United States: concerns and strategies
    Wilson M Compton
    National Institute on Drug Abuse, 6001 Executive Boulevard, MSC 9589, Bethesda, MD 20892 9589, USA
    Drug Alcohol Depend 81:103-7. 2006
    ....
  18. ncbi The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism
    Stine T Zwisler
    Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
    Basic Clin Pharmacol Toxicol 104:335-44. 2009
    b>Oxycodone is O-demethylated by CYP2D6 to oxymorphone which is a potent micro-receptor agonist...
  19. ncbi Postoperative intravenous morphine consumption, pain scores, and side effects with perioperative oral controlled-release oxycodone after lumbar discectomy
    Stephan Blumenthal
    Department of Anesthesiology, Orthopedic University Clinic Zurich Balgrist, Zurich, Switzerland
    Anesth Analg 105:233-7. 2007
    ..In this study, we evaluated the perioperative application of oral controlled-release oxycodone to reduce postoperative IV morphine consumption and opioid side effects after lumbar discectomy.
  20. ncbi Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine
    Minoru Narita
    Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Shinagawa ku, Tokyo, Japan
    Neuropsychopharmacology 33:1097-112. 2008
    The present study was undertaken to investigate pharmacological actions induced by morphine and oxycodone under a neuropathic pain-like state...
  21. ncbi Relationship between rate of infusion and reinforcing strength of oxycodone in humans
    Sandra D Comer
    Department of Psychiatry, Columbia University, New York, New York, USA
    J Opioid Manag 5:203-12. 2009
    ..5-week inpatient study. During test days, participants received $20 and a dose of drug (0 or 40 mg oxycodone administered intravenously over 2, 15, 30, 60, or 90 minutes) in random order during a morning sample session...
  22. ncbi Trends in opioid consumption in the Nordic countries 2002-2006
    Katri Hamunen
    Pain Clinic, Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Central Hospital, Meilahti Hospital, Helsinki, HUS, Finland
    Eur J Pain 13:954-62. 2009
    ..The purpose of the study was to examine the trends in opioid consumption in the five Nordic countries between 2002 and 2006 and to explore possible explanations for changes in the quality and quantity of opioids consumed...
  23. pmc Prenatal oxycodone exposure impairs spatial learning and/or memory in rats
    Chris P Davis
    Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center Shreveport, Shreveport, LA 71130 3932, USA
    Behav Brain Res 212:27-34. 2010
    ..Adult female Sprague-Dawley rats were treated for 30 days via oral gavage with ascending doses of oxycodone HCl up to a final dose of 15mg/kg/day, which was maintained during breeding and gestation...
  24. pmc Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats
    M Pravetoni
    Minneapolis Medical Research Foundation, 600 Shapiro Building, 914 8th Street, Minneapolis, MN 55404, USA
    Vaccine 30:4617-24. 2012
    ..strategy of combining 2 vaccines that could target several of the most commonly abused opioids; heroin, oxycodone and their active metabolites...
  25. ncbi Oxycodone: a review of its use in the management of pain
    Julia Riley
    Department of Palliative Care, The Royal Marsden NHS Trust, London, UK
    Curr Med Res Opin 24:175-92. 2008
    b>Oxycodone is a strong opioid that acts at mu- and kappa-opioid receptors. It has pharmacological actions similar to strong opioids, but with a specific pharmacologic profile and greater analgesic potency to morphine...
  26. ncbi How different is oxycodone from morphine?
    Eija Kalso
    Pain 132:227-8. 2007
  27. pmc Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens
    Marco Pravetoni
    Minneapolis Medical Research Foundation, 701 Park Avenue, Minneapolis, Minnesota 55404, USA
    J Med Chem 56:915-23. 2013
    ..Vaccination against prescription opioids may provide an alternative to pharmacotherapy. An oxycodone hapten containing a tetraglycine linker at the C6 position (6OXY(Gly)(4)OH) conjugated to keyhole limpet ..
  28. ncbi A brief survey to characterize oxycodone abuse patterns in adolescents enrolled in two substance abuse recovery high schools
    Eric D Osgood
    Department of Psychometrics and Outcomes, Analgesic Solutions, Natick, MA 01760, USA
    Am J Drug Alcohol Abuse 38:166-70. 2012
    Although oxycodone is one of the most widely available and abused opioids, little published information exists on the abuse of immediate-release oxycodone.
  29. ncbi Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study
    M Soledad Cepeda
    Janssen Pharmaceutical Research and Development, LLC, Titusville, New Jersey 08560, USA
    J Pain 14:158-64. 2013
    ..cohort study was to compare the risk of shopping behavior between tapentadol immediate release (IR) and oxycodone IR. Subjects exposed to tapentadol or oxycodone with no recent opioid use were included and followed for 1 year...
  30. pmc Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model
    Atsushi Nakamura
    Pain and Neurology, Discovery Research Laboratories, Shionogi Co, Ltd, Toyonaka, Osaka, Japan
    Br J Pharmacol 168:375-88. 2013
    ..Bone cancer pain is chronic and often difficult to control with opioids. However, recent studies have shown that several opioids have distinct analgesic profiles in chronic pain...
  31. ncbi Oxycodone/acetaminophen at low dosage: an alternative pain treatment for patients with rheumatoid arthritis
    William Raffaeli
    Pain Therapy and Palliative Care Unit, Infermi Hospital, Rimini, Italy
    J Opioid Manag 6:40-6. 2010
    To assess efficacy and safety of the association oxycodone/acetaminophen (oxycodone/acetaminophen) for pain treatment and disability improvement in patients with rheumatoid arthritis (RA).
  32. pmc A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
    Sam H Ahmedzai
    School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Palliat Med 26:50-60. 2012
    An examination of whether oxycodone/naloxone prolonged-release tablets (OXN PR) can improve constipation and maintain analgesia, compared with oxycodone prolonged-release tablets (OxyPR) in patients with moderate/severe cancer pain.
  33. ncbi Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
    Margaret T Susce
    University of Kentucky, Mental Health Research Center at Eastern State Hospital, Lexington, KY 40508, USA
    Prog Neuropsychopharmacol Biol Psychiatry 30:1356-8. 2006
    ..CYP2D6 metabolizes other opioid analgesics, including tramadol, dihydrocodeine, oxycodone and hydrocodone, although they have been less systematically studied...
  34. pmc Oxycodone combinations for pain relief
    R B Raffa
    Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA
    Drugs Today (Barc) 46:379-98. 2010
    ..We review here analgesic combinations containing oxycodone. We found surprisingly little preclinical information about the analgesic or adverse effect profiles of the ..
  35. pmc The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers
    Sharon L Walsh
    Department of Behavioral Sciences, Center on Drug and Alcohol Research, University of Kentucky, 515 Oldham Court, Lexington, KY 40502, USA
    Drug Alcohol Depend 98:191-202. 2008
    ..within-subject, placebo-controlled design to examine the relative abuse potential and potency of oral oxycodone (10, 20 and 40 mg), hydrocodone (15, 30 and 45 mg), hydromorphone (10, 17.5 and 25mg) and placebo...
  36. ncbi Oxycodone: new 'old' drug
    Klaus T Olkkola
    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku and Turku University Hospital, Turku, Finland
    Curr Opin Anaesthesiol 22:459-62. 2009
    Since the introduction of oral immediate release and controlled-release oxycodone preparations to the market in the 1990s, the clinical use and scientific interest in oxycodone has increased greatly.
  37. ncbi Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain
    Lars Arendt-Nielsen
    Center for Sensory Motor Interaction, Department of Health Science and Technology, Aalborg University, Denmark
    Anesthesiology 111:616-24. 2009
    ..a peripherally selective tetrapeptide kappa-opioid receptor agonist, CR665, on experimental pain from multi-modal stimulation of skin, muscle, and viscera, and (2) contrast these effects with those of oxycodone (centrally acting opioid).
  38. ncbi High doses of oxycodone-naloxone combination may provide poor analgesia
    Sebastiano Mercadante
    Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Via San Lorenzo 312, 90146, Palermo, Italy
    Support Care Cancer 19:1471-2. 2011
    Several studies have shown that an oxycodone/naloxone combination (ratio 2:1) provides analgesia and less constipation in non-cancer patients receiving relatively low doses of this formulation...
  39. ncbi St John's wort greatly reduces the concentrations of oral oxycodone
    Tuija H Nieminen
    Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital and University of Turku, Turku, Finland
    Eur J Pain 14:854-9. 2010
    ..Chronic pain is associated with depression. Self-treatment of depression with herbal over-the-counter medicine St John's wort makes pain patients prone to drug interactions...
  40. ncbi Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis
    William Dunlop
    Mundipharma International Limited, Cambridge Science Park, Milton Road, Cambridge, UK
    J Med Econ 15:564-75. 2012
    To compare the cost effectiveness of prolonged release oxycodone/naloxone (OXN) tablets (Targinact) and prolonged release oxycodone (OXY) tablets (OxyContin) in patients with moderate-to-severe non-malignant pain and opioid-induced ..
  41. pmc Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone
    Juha Grönlund
    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku and Turku University Hospital, Turku, Finland
    Br J Clin Pharmacol 70:78-87. 2010
    b>Oxycodone is an opioid analgesic that is metabolized mainly in the liver by cytochrome P450 (CYP) 2D6 and 3A4 enzymes...
  42. pmc Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies
    William W Stoops
    Department of Behavioral Science, University of Kentucky College of Medicine, 140 Medical Behavioral Science Building, Lexington, KY 40536 0086, USA
    Psychopharmacology (Berl) 212:193-203. 2010
    ....
  43. ncbi Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone
    Juha Grönlund
    Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku and Turku University Hospital, Turku, Finland
    J Clin Pharmacol 50:101-8. 2010
    ..enzyme activity with telithromycin affects the pharmacokinetics and pharmacodynamics of orally administered oxycodone in a randomized 2-phase crossover study...
  44. ncbi The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients
    K Ma
    Department of Anesthesiology, Shanghai Sixth People s Hospital, Shanghai, China
    Int J Clin Pract 62:241-7. 2008
    ..The aim of this study is to evaluate the efficacy and side effects of oxycondone controlled release (Oxy-CR) in managing chronic neck pain with acute pain episodes...
  45. ncbi Tentative identification of novel oxycodone metabolites in human urine
    Karla A Moore
    Office of the Chief Medical Examiner, State of Maryland, 111 Penn Street, Baltimore, Maryland 21201 1020, USA
    J Anal Toxicol 27:346-52. 2003
    b>Oxycodone is a semisynthetic codeine derivative that has been used both as an analgesic and antitussive...
  46. pmc The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers
    James P Zacny
    Department of Anesthesia and Critical Care, MC4028, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Pharmacol Biochem Behav 94:108-13. 2009
    This study examined the effects of oral oxycodone, a prescription opioid, on several measures of impulsive behavior in healthy volunteers...
  47. pmc The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Switzerland
    Br J Pharmacol 160:907-18. 2010
    ..There is high interindividual variability in the activity of drug-metabolizing enzymes catalysing the oxidation of oxycodone [cytochrome P450 (CYP) 2D6 and 3A], due to genetic polymorphisms and/or drug-drug interactions...
  48. ncbi Opioid therapy for chronic noncancer back pain. A randomized prospective study
    R N Jamison
    Department of Anesthesia, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Spine (Phila Pa 1976) 23:2591-600. 1998
    ..before being randomly assigned to one of three treatment regimens for 16 weeks: 1) naproxen only, 2) set-dose oxycodone, or 3) titrated-dose oxycodone and sustained-release morphine sulfate...
  49. ncbi Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study
    Antonio Gatti
    Dipartimento AFA Servizio di Anestesia e Terapia del Dolore, Ospedale Tor Vergata, Viale Oxford 81, Rome, Italy
    Eur Neurol 61:129-37. 2009
    ..our study was to compare the efficacy, safety, and quality of life of combination therapy with controlled-release (CR) oxycodone plus pregabalin versus monotherapy with either CR oxycodone or pregabalin in patients with neuropathic pain.
  50. pmc Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain
    A Sandner-Kiesling
    Department of Anaesthesiology and Intensive Care Medicine, Medical University, Graz, Austria
    Int J Clin Pract 64:763-74. 2010
    The aim of this study was to assess safety and efficacy of fixed combination oxycodone prolonged release (PR)/naloxone PR in terms of both analgesia and improving opioid-induced bowel dysfunction (OIBD) and associated symptoms, such as ..
  51. ncbi Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
    T Heiskanen
    Department of Anaesthesia, Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 64:603-11. 1998
    b>Oxycodone is metabolized in the liver by means of O-demethylation to form oxymorphone in a reaction catalyzed by the enzyme cytochrome P450 2D6 (CYP2D6). This enzyme is expressed as 2 phenotypes (extensive and poor metabolizers)...
  52. ncbi Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial
    O Lowenstein
    Mundipharma Research GmbH and Co KG, Limburg Lahn, Germany
    Expert Opin Pharmacother 10:531-43. 2009
    ..double-dummy, parallel-group multicentre study assessed the impact of a total daily dose of 60-80 mg oral oxycodone prolonged-release (PR)/naloxone PR (OXN PR) as fixed-ratio combination for patients with opioid-induced ..
  53. ncbi Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain
    E Bruera
    Grey Nuns Community Hospital and Health Centre, Cross Cancer Institute, Division of Palliative Care Medicine, University of Alberta, Edmonton, Canada
    J Clin Oncol 16:3222-9. 1998
    Use of oxycodone for chronic cancer pain has been hampered by its short elimination half-life. This study was designed to compare the efficacy and safety of controlled-release formulations of oxycodone and morphine for cancer pain.
  54. ncbi In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics
    Emma Boström
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    Drug Metab Dispos 34:1624-31. 2006
    The blood-brain barrier (BBB) transport of oxycodone was studied in rats. Microdialysis probes were inserted into the striatum and vena jugularis...
  55. ncbi Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone
    Tuija H Nieminen
    Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital, Turku, Finland
    Anesthesiology 110:1371-8. 2009
    b>Oxycodone is a mu-opioid receptor agonist that is metabolized mainly in the liver by cytochrome P450 3A and 2D6 enzymes. Rifampin is a strong inducer of several drug-metabolizing enzymes...
  56. ncbi Predicting the analgesic effect to oxycodone by 'static' and 'dynamic' quantitative sensory testing in healthy subjects
    Elon Eisenberg
    The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Israel
    Pain 151:104-9. 2010
    ..on 40 healthy volunteers in order to test whether this methodology can predict the analgesic effects of oral oxycodone, as compared to a placebo, on latency to onset, pain intensity, and tolerance to the cold pressor test (CPT)...
  57. pmc Morphine and alternative opioids in cancer pain: the EAPC recommendations
    G W Hanks
    Palliative Medicine, University of Bristol, Bristol Haematology and Oncology Centre, UK
    Br J Cancer 84:587-93. 2001
    ..Practical strategies for dealing with difficult situations are described presenting a consensus view where supporting evidence is lacking. The strength of the evidence on which each recommendation is based is indicated...
  58. ncbi Role of oxycodone and oxycodone/naloxone in cancer pain management
    Wojciech Leppert
    Department of Palliative Medicine, Poznan University of Medical Sciences, Osiedle Rusa 25 A, PL 61 245 Poznań, Poland
    Pharmacol Rep 62:578-91. 2010
    b>Oxycodone is a valued opioid analgesic, which may be administered either as the first strong opioid or when other strong opioids are ineffective...
  59. ncbi Oxycodone-induced analgesic effects in a bone cancer pain model in mice
    Akira Kato
    Pain and Neurology, Discovery Research Laboratories, Shionogi and Co, Ltd, Koka, Japan
    Oncology 74:55-60. 2008
    ..The analgesic effects of oxycodone and other opioids, such as morphine and fentanyl, were evaluated at 14 days when all pain-related behaviors ..
  60. pmc Abuse liability of oxycodone as a function of pain and drug use history
    S D Comer
    Department of Psychiatry, Columbia University and the New York State Psychiatric Institute, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA
    Drug Alcohol Depend 109:130-8. 2010
    ..All participants completed twelve sessions during which the effects of orally delivered oxycodone (0, 15, 30mg/70kg, PO) were examined...
  61. ncbi Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
    Teijo I Saari
    Department of Anesthesiology, University of Turku, Finland
    Eur J Clin Pharmacol 66:387-97. 2010
    The aim of this study was to investigate the effects of the cytochrome P450 3A4 (CYP34A) inhibitor itraconazole on the pharmacokinetics and pharmacodynamics of orally and intravenously administered oxycodone.
  62. ncbi Oxycodone vs. fentanyl in the treatment of early post-operative pain after laparoscopic cholecystectomy: a randomised double-blind study
    S Koch
    Department of Anaesthesiology, Aarhus University Hospital, Aarhus, Denmark
    Acta Anaesthesiol Scand 52:845-50. 2008
    It has been suggested that oxycodone is superior to other opioids in the treatment of visceral pain. We therefore compared the effect of intravenous (i.v.) oxycodone and i.v...
  63. ncbi Efficacy of oxycodone/acetaminophen and codeine/acetaminophen vs. conventional therapy in elderly women with persistent, moderate to severe osteoarthritis-related pain
    Laura Corsinovi
    Section of Geriatrics, Department of Medical and Surgical Disciplines, University of Turin, Ospedale San Giovanni Battista Molinette, Corso Bramante 88, I 10126 Torino, Italy
    Arch Gerontol Geriatr 49:378-82. 2009
    We aimed to evaluate the efficacy and safety of oxycodone/acetaminophen (O/A) and codeine/acetaminophen (C/A) vs...
  64. ncbi The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone
    J Elise Bailey
    Rocky Mountain Poison and Drug Center, Denver Health, CO, USA
    Drug Alcohol Depend 84:182-7. 2006
    Controversy exists concerning whether abuse of oxycodone will increase after the introduction of generic controlled-release (CR) oxycodone...
  65. ncbi Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study
    Russell K Portenoy
    Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
    Clin J Pain 23:287-99. 2007
    To evaluate the outcomes associated with the use of controlled-release (CR) oxycodone for up to 3 years in the treatment of noncancer pain.
  66. pmc Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis
    Hazem E Hassan
    Department of Pharmaceutical Sciences, School of Pharmacy, School of Medicine, University of Maryland, Baltimore, Maryland, USA
    Drug Metab Dispos 38:157-67. 2010
    Although oxycodone is the most often used opioid agonist, it remains one of the most understudied drugs...
  67. pmc Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids
    Beth Sproule
    Centre for Addiction and Mental Health, Toronto, ON
    Can Fam Physician 55:68-9, 69.e1-5. 2009
    To evaluate the clinical observation that the number of individuals seeking opioid detoxification from oxycodone was increasing at the Centre for Addiction and Mental Health (CAMH) in Toronto, Ont; and to identify the characteristics of ..
  68. ncbi Levo-tetrahydropalmatine attenuates oxycodone-induced conditioned place preference in rats
    Yan Li Liu
    College of Pharmacy, Soochow University, Suzhou, China
    Eur J Pharmacol 602:321-7. 2009
    ..studies demonstrated the ability of l-THP to inhibit locomotor stimulation and physical dependence induced by oxycodone in mice and rats...
  69. ncbi Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users
    Kerri A Schoedel
    Kendle Early Stage, Toronto, Ontario, Canada
    J Opioid Manag 7:179-92. 2011
    To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR).
  70. ncbi Voriconazole drastically increases exposure to oral oxycodone
    Nora M Hagelberg
    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital, PO Box 52 Kiinamyllynkatu 4 8, FI 20521 Turku, Finland
    Eur J Clin Pharmacol 65:263-71. 2009
    We investigated the effect of voriconazole on the pharmacokinetics and pharmacodynamics of oxycodone.
  71. ncbi Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation
    A M Rentz
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
    J Med Econ 12:371-83. 2009
    ..The objective of the present analysis was to evaluate the psychometric characteristics of the BFI using data from clinical studies of oral prolonged release (PR) oxycodone/naloxone.
  72. ncbi Morphine versus oxycodone analgesia after percutaneous kidney stone surgery: a randomised double blinded study
    Katja Venborg Pedersen
    Urological Research Centre, Department of Urology, Fredericia Hospital part of Hospital Littlebelt, University of Southern Denmark, Dronningensgade 97, 7000, Fredericia, Denmark
    Urolithiasis 41:423-30. 2013
    According to previous studies oxycodone might have some advantages over morphine in the treatment of visceral pain...
  73. ncbi Toxicology and characteristics of fatal oxycodone toxicity cases in New South Wales, Australia 1999-2008
    Shane Darke
    National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia
    J Forensic Sci 56:690-3. 2011
    All cases of fatal oxycodone toxicity presenting to the New South Wales Department of Forensic Medicine over the period January 1, 1999, to December 31, 2008, were retrieved. A total of 70 cases were identified. The mean age was 48...
  74. ncbi Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: a randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model
    Scott Korn
    Merck Research Laboratories, BLA 33, Bluebell, PA 19422, USA
    Clin Ther 26:769-78. 2004
    ..Rofecoxib has demonstrated an improved gastrointestinal safety profile compared with nonselective NSAIDs...
  75. ncbi CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone
    Takafumi Naito
    Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1 20 1 Handayama, Higashi ku, Hamamatsu, Shizuoka 431 3192, Japan
    J Clin Pharmacol 51:1529-38. 2011
    The aim of this study was to evaluate the plasma dispositions of oxycodone and its demethylates and dose escalation based on genetic polymorphisms of CYP2D6, CYP3A5, ABCB1, and OPRM1 in cancer patients receiving oxycodone...
  76. ncbi Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:296-304. 2003
    This randomized, controlled trial compared the analgesic efficacy and safety of the new oxycodone 10-mg/acetaminophen 325-mg formulation (Percocet) for the treatment of acute pain following oral surgery with double the dose of oxycodone ..
  77. ncbi Effects of carbamazepine/oxycodone coadministration in the treatment of trigeminal neuralgia
    Antonio Siniscalchi
    Department of Neuroscience, Neurology Division, Annunziata Hospital, Cosenza, Italy
    Ann Pharmacother 45:e33. 2011
    To report on a patient with trigeminal neuralgia who responded positively to combined carbamazepine/oxycodone treatment.
  78. ncbi A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia
    Anne E Olesen
    Mech Sense, Department of Gastroenterology, Aalborg Hospital, Aarhus University Hospital, Aarhus, Denmark
    Clin Pharmacokinet 49:817-27. 2010
    b>Oxycodone is not as well characterized, with respect to its pharmacokinetic/pharmacodynamic properties, as other opioids. Moreover, the pharmacodynamic profile of oxycodone can be affected by changes in the pain system, e.g. hyperalgesia...
  79. pmc Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers
    Ziva D Cooper
    Department of Psychiatry, Division on Substance Abuse, New York Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    Behav Pharmacol 23:271-9. 2012
    ..tolerance developed to the analgesic, subjective, and physiological effects of the commonly prescribed opioid oxycodone when it was administered daily for 5 days...
  80. ncbi Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients
    Takafumi Naito
    Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1 20 1 Handayama, Higashi ku, Hamamatsu, Shizuoka, 431 3192, Japan
    Eur J Clin Pharmacol 68:1411-8. 2012
    ..The aim of this study was to evaluate the influence of cachexia on the pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.
  81. ncbi Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers
    James P Zacny
    Department of Anesthesia and Critical Care MC 4028, The Pritzker School of Medicine, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Psychopharmacology (Berl) 170:242-54. 2003
    The subjective, psychomotor, and physiological effects of a widely prescribed and abused prescription opioid, oxycodone, have not been studied in a population of non-drug-abusing people.
  82. ncbi Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer
    K E Clemens
    Department of Science and Research, Centre for Palliative Medicine, University of Bonn, Bonn, Germany
    Int J Clin Pract 65:472-8. 2011
    ..The aim of the study was to evaluate whether patients with advanced cancer and moderate to severe cancer pain will benefit from treatment with oxycodone/naloxone prolonged-release tablets (OXN), with particular regard to constipation.
  83. ncbi Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
    Tuija H Nieminen
    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital and University of Turku, P O Box 52, Kiinamyllynkatu 4 8, 20521 Turku, Finland
    Eur J Clin Pharmacol 66:977-85. 2010
    ..study aimed to investigate the effect of antivirals ritonavir and lopinavir/ritonavir on the pharmacokinetics and pharmacodynamics of oral oxycodone, a widely used opioid receptor agonist used in the treatment of moderate to severe pain.
  84. ncbi Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice
    U Schutter
    Schmerztherapeutische Schwerpunktpraxis, Marl, Germany
    Curr Med Res Opin 26:1377-87. 2010
    ..Chronic pain has a marked negative impact on quality of life. Opioid treatment is often effective in controlling this pain, but it has numerous side-effects, particularly affecting bowel function...
  85. ncbi Severe leukoencephalopathy following acute oxycodone intoxication
    Yazmin Morales Odia
    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Neurocrit Care 13:93-7. 2010
    ..Post-opioid toxic encephalopathy is described associated with the synthetic opioid, methadone, and after heroin intoxication, (inhaled, injected or ingested)...
  86. ncbi Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation
    Antonio Gatti
    Anaesthesiology Department, Policlinic and University Tor Vergata, Roma, Italy
    Adv Ther 30:41-59. 2013
    ..A prolonged-released (PR) fixed-dose combination of oxycodone and naloxone has been developed and efficacy has been demonstrated in phase 3 clinical trials.
  87. pmc Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Geneva, Switzerland
    Br J Pharmacol 160:919-30. 2010
    The major drug-metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A...
  88. pmc Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study
    Anne Estrup Olesen
    Mech Sense, Department of Gastroenterology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
    Br J Clin Pharmacol 70:189-200. 2010
    ..WHAT THIS STUDY ADDS? * We now know that morphine and oxycodone exerts different effects in the sensitized pain system as we found a greater analgesic effect of oxycodone in ..
  89. ncbi Analgesic concentrations of oxycodone--a prospective clinical PK/PD study in patients with laparoscopic cholecystectomy
    Merja Kokki
    Department of Anesthesiology and Intensive Care, Kuopio University Hospital, Kuopio, Finland
    Basic Clin Pharmacol Toxicol 110:469-75. 2012
    The analgesic concentrations of oxycodone in acute post-operative pain management have not been established...
  90. ncbi Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products
    James P Zacny
    Department of Anesthesia and Critical Care, University of Chicago, Chicago, Illinois 60637, USA
    Pain Med 9:433-43. 2008
    To compare within the same individuals two typically prescribed doses of hydrocodone/acetaminophen and oxycodone/acetaminophen products for their subjective, psychomotor, and physiological effects in healthy volunteers.
  91. ncbi Oxycodone abuse in Texas, 1998-2004
    Mathias B Forrester
    Texas Department of State Health Services, Austin, Texas 78756, USA
    J Toxicol Environ Health A 70:534-8. 2007
    b>Oxycodone is frequently abused, and this abuse appears to be increasing. The purpose of this study was to describe the patterns of oxycodone abuse identified by Texas poison control centers...
  92. ncbi Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites
    Bojan Lalovic
    Department of Pharmaceutics, University of Washington, Seattle 98195, USA
    Clin Pharmacol Ther 79:461-79. 2006
    In vitro experiments suggest that circulating metabolites of oxycodone are opioid receptor agonists...
  93. ncbi Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat
    Kim Lemberg
    Department of Pharmacology, Institute of Biomedicine, University of Helsinki, Finland
    Anesth Analg 102:1768-74. 2006
    We studied the effects of the commonly used mu-opioid receptor agonists morphine, oxycodone, methadone and the enantiomers of methadone in thermal and mechanical models of acute pain and in the spinal nerve ligation model of neuropathic ..
  94. ncbi Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo
    Muhammad Waqas Sadiq
    Department of Pharmaceutical Biosciences, Uppsala University, SE 75124 Uppsala, Sweden
    J Pharm Sci 100:3912-23. 2011
    Diphenhydramine (DPHM) and oxycodone are weak bases that are able to form cations. Both drugs show active uptake at the blood-brain barrier (BBB)...
  95. pmc Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4
    Juha Grönlund
    Department of Anesthesiology, Intensive Care, Emergency Care, and Pain Medicine, University of Turku, P O Box 52, Kiinamyllynkatu 4 8, FI 20520 Turku, Finland
    Antimicrob Agents Chemother 55:1063-7. 2011
    Our aim was to assess the effect of miconazole oral gel on the pharmacokinetics of oral oxycodone. In an open crossover study with two phases, 12 healthy volunteers took a single oral dose of 10 mg of immediate-release oxycodone with or ..
  96. ncbi Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain
    Nadav Friedmann
    Pain Therapeutics, Inc, San Mateo, California 94404, USA
    Pain Med 12:755-60. 2011
    Evaluate the long-term safety, tolerability, and efficacy of Remoxy® (extended-release oxycodone) in patients with chronic pain related to osteoarthritis of the hip and/or knee or chronic low back pain.
  97. ncbi Sevoflurane versus halothane: effect of oxycodone premedication on emergence behaviour in children
    David J Murray
    Department of Anesthesiology, Washington University at St Louis Children s Hospital, St Louis, MO 63110, USA
    Paediatr Anaesth 12:308-12. 2002
    ..The purpose of the study was to determine a frequency and duration of agitation with halothane and sevoflurane anaesthesia and whether oxycodone premedication affected the incidence of emergence agitation in children.
  98. ncbi [Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state]
    Imai Satoshi
    Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2 4 41 Ebara, Shinagawa ku, Tokyo 142 8501, Japan
    Nihon Shinkei Seishin Yakurigaku Zasshi 28:169-76. 2008
    In the present study, we demonstrated that repeated treatment with fentanyl, but not morphine or oxycodone, causes a rapid desensitization to its ability to block the hyperalgesia associated with the attenuation of mu-opioid receptor ..
  99. ncbi Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases
    Paul J Jannetto
    Milwaukee County Medical Examiner s Office, Wisconsin, USA
    J Anal Toxicol 26:438-47. 2002
    ..b>Oxycodone, frequently prescribed for the relief of moderate to severe pain, is metabolized by cytochrome P450 (CYP) 2D6, ..
  100. ncbi Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice
    K Kuusniemi
    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital and University of Turku, Turku, Finland
    J Int Med Res 40:1775-93. 2012
    These studies evaluated the feasibility of using oral prolonged-release oxycodone/naloxone (OXN PR) for the management of acute postoperative pain.
  101. ncbi Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, Chadds Ford, Pennsylvania 19317, USA
    Pain Med 4:21-30. 2003
    To evaluate the analgesic effectiveness/safety of the new oxycodone 7...

Research Grants64

  1. 18F-beta-Endorphin Imaging: Translational Study of an Opioid Peptide Radiotracer
    BRIAN contact REED; Fiscal Year: 2010
    ..receptors (MOP-r), the target of addictive opioids such as heroin and prescription opioid analgesics such as oxycodone and morphine...
  2. Genetic Basis of Opioid Reward and Aversion in Mice
    Camron D Bryant; Fiscal Year: 2012
    ..assay- to screen for differences in the rewarding response to the commonly abused prescription opioid agonist oxycodone (OXY) and the aversive response to the opioid antagonist naloxone (NAL)...
  3. Genetic Basis of Opioid Reward and Aversion in Mice
    Camron D Bryant; Fiscal Year: 2013
    ..assay- to screen for differences in the rewarding response to the commonly abused prescription opioid agonist oxycodone (OXY) and the aversive response to the opioid antagonist naloxone (NAL)...
  4. Opioid selection and the risk of serious infections in older adults
    Carlos G Grijalva; Fiscal Year: 2013
    ..users of other opioids with comparable analgesic properties;and, 3) Test the hypothesis that concurrent use of oxycodone or methadone and strong inhibitors of their metabolism increases the risk of serious infections relative to such ..
  5. Social Influences on drug reward and monoamines
    Sondra T Bland; Fiscal Year: 2010
    ..research addresses these issues by asking the following questions: Do social cues during exposure to the opioid oxycodone or the psychostimulant cocaine have a greater impact on drug seeking behavior in male and female rats that have ..
  6. Licit &Illicit Opioids: Comparative Studies in Humans
    Sharon L Walsh; Fiscal Year: 2013
    ..by conducting a series of studies on the clinical pharmacology of the most widely abused opioids (hydrocodone, oxycodone and Oxycontin(R))...
  7. Drug-Drug Interactions and Preventable Adverse Events in Rheumatology
    CECILIA PILAR CHUNG; Fiscal Year: 2013
    ..assemble cohorts receiving selected CYP3A substrate drugs with great potential for toxicity: (1) the opioids oxycodone and fentanyl and (2) colchicine users and define the risk of clinically important outcomes associated with ..
  8. Exogenous Chemical Probes of TLR-Mediated Neuroinflammation
    HANG HUBERT YIN; Fiscal Year: 2013
    ..g. morphine, methadone, meperidine, and oxycodone) and that this opioid-induced glial response suppresses opioid analgesia, resulting in the development of opioid ..
  9. Contribution of Various Genetic Polymorphisms to Oxycodone's Abuse Liability
    Jermaine D Jones; Fiscal Year: 2013
    ..We will attempt to elucidate the relationship between 3 common gene variants and the abuse liability of oxycodone. Currently, the abuse of prescription opioid medications is a pervasive social problem in the U.S...
  10. Early antigen-specific B cell responses as markers of oxycodone vaccine efficacy
    Marco Pravetoni; Fiscal Year: 2013
    ..Specifically oxycodone (OXY)-specific B cells will be compared between different OXY vaccines and will correlate with OXY-specific ..
  11. Methods for the Development of Arrestin2 Inhibitors.
    Spiro Pavlopoulos; Fiscal Year: 2010
    ..This work will lead to the development of tools to better understand these processes and may contribute to the design of therapeutic agents that help to treat addiction and circumvent tolerance to therapeutic drugs. ..
  12. The Prescriber Opioid Risk Reduction Strategies (PORRS) Study
    Jeanine K Mount; Fiscal Year: 2013
    ..Primary concerns focus on adolescent and adult populations aged 15-64. Opioids of greatest concern (e.g., oxycodone, hydrocodone, methadone, morphine, codeine) are found in single- entity and combination drug products ..
  13. Mechanisms of Carisoprodol Abuse
    Laszlo Prokai; Fiscal Year: 2012
    ..later, the Drug Abuse Warning Network identified carisoprodol as the 14th most abused drug, ranking higher than oxycodone, methadone, and LSD...
  14. Adolescent Oxycodone Self Administration and Vulnerability to Opiate Abuse
    Yong Zhang; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Abuse of prescription opioid analgesics (such as oxycodone) has become a major health concern in the United States and occurs mostly in adolescents and young adults...
  15. Prescribed Opioid Safety in Children
    Wayne A Ray; Fiscal Year: 2013
    ..Potentially hazardous practices include higher doses, high-potency opioids such as oxycodone, and concurrent central nervous system depressants...
  16. The process of long term abstinence from opioid use among HIV+ respondents
    Nelson Jose Tiburcio; Fiscal Year: 2012
    ..This study holds promise for informing future interventions and sketching a roadmap to maintenance of recovery and wellness as demonstrated by HIV+ people with lived experience/s of abstinence from substance use. ..
  17. Online Buprenorphine Training for Outreach Workers and Case Managers
    JANIE ELIZABETH SIMMONS; Fiscal Year: 2010
    ..The curriculum will be marketed to a broad range of profit and non-profit organizations and institutions. ..
  18. Naloxone Nasal Spray Development
    DANIEL PAUL WERMELING; Fiscal Year: 2013
    ..Conduct a human nasal tolerability study of the final formulation ..
  19. Characterization of the Role of mTOR Signaling in Opiate Action
    MICHELLE SUZANNE MAZEI ROBISON; Fiscal Year: 2010
    ....
  20. Drug Self Administration and Withdrawal Effects on Cognitive Function
    Brian D Kangas; Fiscal Year: 2013
    ..have high dependence and abuse liability (tetrahydrocannabinol [9-THC], the active ingredient in marijuana, and oxycodone, and the prescription opioid analgesic) on different aspects of cognition...
  21. T. brucei: next-generation platform for immunization against drugs of abuse
    Pete Stavropoulos; Fiscal Year: 2013
    ..provided by applicant): Abuse and addiction to prescription opioids (short-acting MOP-r agonists such as oxycodone) have reached epidemic proportions in the US...
  22. Prescription Opioid Effects in Drug and Non-drug Abusers
    Sandra D Comer; Fiscal Year: 2013
    ..A study conducted during our previous award period revealed that oral oxycodone elicited similar subjective effects in drug abusers and non-drug abusers, but the self-administration patterns ..
  23. COPE-P: Shared Decision-Making Aid for Patients Regarding Chronic Opioid Therapy
    Susan A Stoner; Fiscal Year: 2010
    ..We propose to develop a web-based program to help patients, along with their healthcare teams, learn about and decide whether to utilize chronic opioid therapy or other alternatives. ..
  24. Epidemiologic Study of the Effectiveness of an ADF in Reducing Opioid Abuse
    Jennifer R Havens; Fiscal Year: 2013
    ..The results from this study, in turn, will have vast implications for not only public health, but aso policies surrounding development of ADFs in order to prevent abuse of prescription opioids. ..
  25. BEHAVIORAL EFFECTS OF OPIOIDS IN VOLUNTEERS
    James Zacny; Fiscal Year: 2003
    ..studies in normal volunteers, focusing on four oral drugs commonly used in outpatient settings: hydrocodone, oxycodone, propoxyphene, and tramadol...
  26. Internet as Supplier: Preventing Adolescent Use of Non-Medical Addictive Rx
    Amelia M Arria; Fiscal Year: 2010
    ..This study will obtain information directly from adolescents about their use of the internet and other sources to obtain drugs. ..
  27. Herb-Opioid Interactions
    Danny Shen; Fiscal Year: 2003
    ..proposal is to investigate if significant interactions occur between two widely used opioid analgesics - oxycodone and fentanyl and St. John wort extract through laboratory-based studies in healthy volunteers...
  28. Predictors of Relapse to Prescription Opioid Abuse Among Pain Patients
    Maria A Sullivan; Fiscal Year: 2010
    ..goal of this proposal is to address the growing problem of prescription opioid abuse by examining the effects of oxycodone in a laboratory setting in the presence of clinical pain and following significant pain relief following ..
  29. Changes in Homicide and Drug Overdose in New York City
    Kenneth Tardiff; Fiscal Year: 2006
    ..and other fatal accidents with a focus on identifying the emerging role of newer drugs such as ecstasy and oxycodone. 2) To determine neighborhood-level determinants of homicide (e.g...
  30. Hyperalgesia in Methadone Patients: Can it be Treated?
    Margaret Compton; Fiscal Year: 2007
    ..of opioid-induced hyperalgesia, (2) gabapentin, which has proven efficacy in treating neuropathic pain, and (3) oxycodone, which has novel opioid activity, will each be evaluated for its ability to ameliorate or diminish the opioid-..
  31. Opioid Mortality in Southwestern Virginia
    MARTHA WUNSCH; Fiscal Year: 2006
    ..The opioid drugs oxycodone, methadone, and fentanyl were identified as the direct or contributing cause of death...
  32. Opioid and Cannabinoid Pharmacokinetic Interactions
    Donald Abrams; Fiscal Year: 2007
    ..prescribed oral controlled-released morphine (MS Contin(r)) and 10 patients prescribed oral controlled-released oxycodone (OxyContin(r)) to assess the effect of smoking cannabis on the 12-hour plasma area-under-the-curve of these ..
  33. An in situ Opioid Drug Deactivation Kit for Home Use
    SHANTHASHANTHA SARANGAPANI; Fiscal Year: 2013
    ..1: In this objective, the Contractor shall obtain the pure and pharmaceutical forms of codeine, morphine, oxycodone and fentanyl from DEA-certified commercial distributor(s) as well as other materials required for testing of the ..
  34. Modulation of Opioid Effects by Garlic Supplements
    Danny Shen; Fiscal Year: 2007
    ..this proposal is to assess the likelihood of a clinically significant interaction between garlic supplements and oxycodone-a commonly used oral opioid for the treatment of cancer pain...
  35. Abuse-deterrent sustained-release hydromorphone
    MICHAEL ZAMLOOT; Fiscal Year: 2006
    ..The abuse of oxycodone (Purdue Pharma's "OxyContin(tm)") and the resulting risk to public health and safety has been highly ..
  36. Prescription Opioids Among Street Drug Users: Medical Use, Misuse & Diversion
    William R Davis; Fiscal Year: 2010
    ..The research will provide systematic, longitudinal evidence about the extent of medical use, misuse, and diversion of POs within this population to help inform drug abuse control efforts. ..
  37. COPE-N: Interactive education on opioid management of chronic pain for nurses
    Susan Stoner; Fiscal Year: 2009
    ..Prescription opioids are now the top cause of accidental drug overdose. New strategies for assuring quality pain care and limiting harm from opioid abuse are urgently needed. ..
  38. Functional Neuroimaging of Opioid Effects on Affective Experience
    K Luan Phan; Fiscal Year: 2007
    ..S., with costly public health consequences. Opioids, such as oxycodone, tend produce feelings of well-being and pleasure (e.g...
  39. Treatment of Chronic Pain - Consumer and Provider Conce*
    Carole Upshur; Fiscal Year: 2003
    ..management?; and 3) In what ways do provider and patient concerns and identified barriers converge or diverge and how do these convergences or divergences appear to relate to patient satisfaction and outcomes? ..
  40. BEHAVIORAL EFFECTS OF OPIOIDS IN VOLUNTEERS
    James Zacny; Fiscal Year: 2009
    ..by studying different doses of different opioids within the same study and within the same individual (Study 1: oxycodone versus hydrocodone;Study 2: oxycodone versus morphine)...
  41. Abuse-Related Effects of Opioids and Adjuvant Drug Used by Chronic Pain Patients
    James P Zacny; Fiscal Year: 2010
    ..of three studies: using an abuse liability assessment methodology we will examine the interactions of oral oxycodone, a drug prescribed for CNMP and that has abuse liability, and two adjuvant drugs from each of three different ..
  42. Opiate drug abuse and CNS vulnerability to HIV
    Kurt Hauser; Fiscal Year: 2009
    ..Opiate drugs, such as heroin and oxycodone, intrinsically disrupt CNS function, by interfering with endogenous opioid and neuroimmune function...
  43. CHARACTERIZING PSYCHOACTIVE EFFECTS OF INHALANTS
    James Zacny; Fiscal Year: 2004
    ..In short, in our two proposed series of studies, we are developing a human laboratory model of inhalant abuse by studying potential determinants of abuse liability of inhalants (volatile and gaseous) in healthy volunteers. ..
  44. Pain Medication Use & Risk Factors for Opioid Dependence
    Daniel Solomon; Fiscal Year: 2004
    ..Our goal is to use the results of the proposed research to inform a future intervention to improve opioid prescribing within this large pharmacy benefits program. ..
  45. Molecular Genetics of Inattention in Australia
    THEODORE CICERO; Fiscal Year: 2009
    ..This will be at a marked cost savings due to the employment of existing well-characterized samples and the long history of collaborative studies between investigators from Australia and the United States. ..
  46. OPIATE ENDOCRINE INTERACTIONS--DEVELOPMENTAL ASPECTS
    THEODORE CICERO; Fiscal Year: 2003
    ..The proposed animal studies could establish whether gender differences exist and if these differences are based on inherent, first-order biological differences between the sexes. ..
  47. Joint Action Analysis of Poly-drug Withdrawal
    Robert Raffa; Fiscal Year: 2006
    ..g., electrophysiologic or molecular biology techniques. An improved understanding of how withdrawal is influenced by poly-drug abuse could lead to development of enhanced clinical treatment. ..
  48. New Neural Targets for Opioid Use Disorders: Human Studies
    Sharon L Walsh; Fiscal Year: 2010
    ..1 will examine the effects of acute doses of aprepitant alone and in combination with acute doses of oral oxycodone and intranasal oxycodone in non-dependent opioid abusers (n=10)...
  49. THERAPEUTIC POTENTIAL OF KAPPA-OPIOIDS AGAINST COCAINE
    Sharon Walsh; Fiscal Year: 2002
    ..These studies are relevant to the treatment of cocaine abuse and may lead to the development of an effective pharmacotherapy, thereby, reducing the HIV and other health risks associated with cocaine abuse and intravenous drug abuse. ..
  50. PAIN AND ANALGESIC RESPONSE--SEX AND HORMONE VARIATIONS
    Sandra Comer; Fiscal Year: 2002
    ..In addition, they will more carefully examine sex differences in analgesic response to butorphanol and morphine, two agonists with differing selectivities for mu and kappa opioid receptors. ..
  51. Factors in Drug Dependence
    Sharon Walsh; Fiscal Year: 2005
    ..abstract_text> ..
  52. BUPRENORPHINE ABUSE BY HUMANS--LABORATORY STUDIES
    Sandra Comer; Fiscal Year: 2002
    ....
  53. Evaluation of Novel Treatments for Stimulant Dependence
    Sharon Walsh; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  54. Sustained-Release Naltrexone for Opioid Dependence: Longitudinal Study in Humans
    Sandra D Comer; Fiscal Year: 2010
    ....
  55. Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
    Sharon Walsh; Fiscal Year: 2008
    ..This study will provide preliminary safety and efficacy data on the potential utility of atomoxetine and determine whether a larger-scale evaluation is warranted. [unreadable] [unreadable] [unreadable]..
  56. A Spanish Adaptation of the ASI-Multimedia Version
    Stephen Butler; Fiscal Year: 2002
    ..Due to its reliability and low cost, we believe the ASI-MV could become the "Gold Standard" addictions assessment. Under such a circumstance, a Spanish adaptation would enjoy widespread use and profitability. ..
  57. Signal Detection for Prescription Opioid Outbreaks
    Stephen Butler; Fiscal Year: 2008
    ..This system should be perceived by stakeholders as highly valuable. Thus, we believe this product has enormous commercial viability and public health importance. [unreadable] [unreadable] [unreadable] [unreadable]..
  58. WEB-BASED MANAGEMENT TRAINING: ADDICTION-RESOURCES.COM
    Stephen Butler; Fiscal Year: 2003
    ..An analogue field trial will examine, in contrast to a written booklet and wait-list control, the website's effectiveness in facilitating managers to more use of clinical data in decision-making. ..
  59. Pain Assessment Interview and Clinical Advisory System
    Stephen Butler; Fiscal Year: 2008
    ..Thus, we believe this product has enormous commercial viability and public health importance. [unreadable] [unreadable] [unreadable] [unreadable]..
  60. Treatment of Fear and Pain in Irritable Bowel Syndrome
    Bruce Naliboff; Fiscal Year: 2006
    ..abstract_text> ..
  61. A Chinese Adaptation of the ASI-Multimedia Version
    Stephen Butler; Fiscal Year: 2004
    ..The final product will be marketed as part of our extensive suite of substance abuse-related, multimedia tools. ..
  62. Computerized ASI Follow-up and Outcome System
    Stephen Butler; Fiscal Year: 2004
    ..Client acceptance will be evaluated along with correspondence between the IVR and traditional ASI administration. Phase II will evaluate the system's validity, capacity to produce acceptable response rates, and cost-effectiveness. ..
  63. ASI-MV.net: A Prescription Medication Monitoring Tool
    Stephen Butler; Fiscal Year: 2006
    ..Phase II will fully develop the ASI-MV.net website and establish its reliability and validity. The ASI-MV.net will be an innovative solution to problems collecting product-specific addictions data in real time. [unreadable] [unreadable]..